These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 37652210)
1. What can we learn from COVID-19 to improve opioid treatment? Expert providers respond. Harris LM; Marsh JC; Khachikian T; Serrett V; Kong Y; Guerrero EG J Subst Use Addict Treat; 2023 Nov; 154():209157. PubMed ID: 37652210 [TBL] [Abstract][Full Text] [Related]
2. Response to coronavirus 2019 in Veterans Health Administration facilities participating in an implementation initiative to enhance access to medication for opioid use disorder. Gustavson AM; Gordon AJ; Kenny ME; McHenry H; Gronek J; Ackland PE; Hagedorn HJ Subst Abus; 2020; 41(4):413-418. PubMed ID: 32936695 [TBL] [Abstract][Full Text] [Related]
3. Early innovations in opioid use disorder treatment and harm reduction during the COVID-19 pandemic: a scoping review. Krawczyk N; Fawole A; Yang J; Tofighi B Addict Sci Clin Pract; 2021 Nov; 16(1):68. PubMed ID: 34774106 [TBL] [Abstract][Full Text] [Related]
4. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth. Cales RH; Cales SC; Shreffler J; Huecker MR J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567 [TBL] [Abstract][Full Text] [Related]
6. Assessment of State and Federal Health Policies for Opioid Use Disorder Treatment During the COVID-19 Pandemic and Beyond. Pessar SC; Boustead A; Ge Y; Smart R; Pacula RL JAMA Health Forum; 2021 Nov; 2(11):e213833. PubMed ID: 35647581 [TBL] [Abstract][Full Text] [Related]
7. Co-Constructing a Community-Based Telemedicine Program for People With Opioid Use Disorder During the COVID-19 Pandemic: Lessons Learned and Implications for Future Service Delivery. Høj SB; de Montigny C; Chougar S; Léandre R; Beauchemin-Nadeau MÈ; Boyer-Legault G; Goyette A; Lamont SK; Bruneau J JMIR Public Health Surveill; 2023 Jul; 9():e39236. PubMed ID: 37494097 [TBL] [Abstract][Full Text] [Related]
8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198 [TBL] [Abstract][Full Text] [Related]
9. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment. Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469 [No Abstract] [Full Text] [Related]
10. Rapid adaptation during the COVID crisis: Challenges experienced in delivering service to those with Opioid Use Disorders. Hills HA; Lengnick-Hall R; Johnson KA; Vermeer W; Hendricks Brown C; McGovern M Implement Res Pract; 2022; 3():26334895221096295. PubMed ID: 37091103 [TBL] [Abstract][Full Text] [Related]
11. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic. Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913 [TBL] [Abstract][Full Text] [Related]
12. The impact of COVID-19 on substance use disorder treatment in California: Service providers' perspectives. Lin C; Clingan SE; Cousins SJ; Valdez J; Mooney LJ; Hser YI J Subst Abuse Treat; 2022 Feb; 133():108544. PubMed ID: 34183213 [TBL] [Abstract][Full Text] [Related]
13. COVID-19: A catalyst for change in telehealth service delivery for opioid use disorder management. Mehtani NJ; Ristau JT; Snyder H; Surlyn C; Eveland J; Smith-Bernardin S; Knight KR Subst Abus; 2021; 42(2):205-212. PubMed ID: 33684331 [TBL] [Abstract][Full Text] [Related]
14. Common themes in early state policy responses to substance use disorder treatment during COVID-19. Andraka-Christou B; Bouskill K; Haffajee RL; Randall-Kosich O; Golan M; Totaram R; Gordon AJ; Stein BD Am J Drug Alcohol Abuse; 2021 Jul; 47(4):486-496. PubMed ID: 33909518 [No Abstract] [Full Text] [Related]
15. Employing telehealth strategies for opioid addiction during COVID-19: implications for social work health care. Kim SH; Tesmer O Soc Work Health Care; 2021 Aug; 60(6-7):499-508. PubMed ID: 34278979 [TBL] [Abstract][Full Text] [Related]
16. Telehealth for opioid use disorder treatment in low-barrier clinic settings: an exploration of clinician and staff perspectives. Aronowitz SV; Engel-Rebitzer E; Dolan A; Oyekanmi K; Mandell D; Meisel Z; South E; Lowenstein M Harm Reduct J; 2021 Nov; 18(1):119. PubMed ID: 34823538 [TBL] [Abstract][Full Text] [Related]
17. Take home injectable opioids for opioid use disorder during and after the COVID-19 Pandemic is in urgent need: a case study. Oviedo-Joekes E; MacDonald S; Boissonneault C; Harper K Subst Abuse Treat Prev Policy; 2021 Mar; 16(1):22. PubMed ID: 33673847 [TBL] [Abstract][Full Text] [Related]
18. Rapid Transition to Telehealth and the Digital Divide: Implications for Primary Care Access and Equity in a Post-COVID Era. Chang JE; Lai AY; Gupta A; Nguyen AM; Berry CA; Shelley DR Milbank Q; 2021 Jun; 99(2):340-368. PubMed ID: 34075622 [TBL] [Abstract][Full Text] [Related]